Eli Lilly's CEO revealed that one-third of new patients taking GLP-1 pills are using their drug, Foundayo. The company is increasing production to compete with Novo Nordisk, who already has a large market share in the space.
מקור: Business News — לכתבה המלאה
כתיבת תגובה